Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 97208
Upon the closing of the transaction, Licensee will opt-in to patisiran (ALN-TTR02) â€“ an RNAi therapeutic currently in a Phase 3 trial for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR) patients with Familial Amyloidotic Polyneuropathy â€“ for its ROW territories, while Licensor retains full product rights in North America and Western Europe. The parties have also agreed to expand their current collaboration on ALN-TTRsc â€“ an RNAi therapeutic currently in a Phase 2 trial for the treatment of ATTR patients with TTR amyloid cardiomyopathy â€“ where the parties will co-develop and co-promote ALN-TTRsc in North America and Western Europe; Licensor will maintain development and commercialization control with ALN-TTRsc and Licensee will develop and commercialize the product in its ROW territories.
IPSCIO Record ID: 233131
TTR products, including patisiran, ALN-TTRsc02 and any back-up products, referred to as the Exclusive TTR License, and the ALN-AT3 Global License.
The products are investigational RNAi therapeutics and are focused in three Strategic Therapeutic Areas, or â€œSTArsâ€ Genetic Medicines; Cardio-Metabolic Diseases; and Hepatic Infectious Diseases.
Fitusiran is an investigational RNAi therapeutic in development for the treatment of hemophilia A and B with or without inhibitors. The Fitusiran clinical development program is for the treatment of hemophilia and other rare bleeding disorder.
IPSCIO Record ID: 255741
Onpattro is designed to interfere with RNA production of an abnormal form of the protein transthyretin (TTR). By preventing the production of TTR, the drug is intended to help reduce the accumulation of amyloid deposits in peripheral nerves, improving symptoms and helping patients better manage their polyneuropathy.
IPSCIO Record ID: 219860
IPSCIO Record ID: 277007
Hereditary transthyretin-mediated amyloidosis is a genetic, life-threatening disease that is marked by abnormal buildup of the transthyretin protein in peripheral nerves, the heart and elsewhere in the body.
hATTR amyloidosis is a rare, inherited, rapidly progressive and life-threatening disease with a constellation of manifestations. In addition to polyneuropathy, hATTR amyloidosis can lead to other significant disabilities including decreased ambulation with the loss of the ability to walk unaided, a reduced quality of life, and a decline in cardiac functioning.